IRD Q1 2024 Earnings — Opus Genetics, Inc. Revenue & Financial Results | Market Cap Arena

IRDOpus Genetics, Inc.

$349M

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M-2.2% YoY

Gross Profit

$2M100.0% margin

Operating Income

-$8M-450.5% margin

Net Income

-$7M-415.3% margin

EPS (Diluted)

$-0.29

QoQ Revenue Growth

+1.2%

Cash Flow

Operating Cash Flow

-$6M

Free Cash Flow

-$6M

Stock-Based Comp.

$985,000

Balance Sheet

Total Assets

$52M

Total Liabilities

$6M

Stockholders' Equity

$46M

Cash & Equivalents

$47M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$2M	-2.2%
Gross Profit	$2M	-$4M	+144.5%
Operating Income	-$8M	-$6M	-25.7%
Net Income	-$7M	-$6M	-22.7%